Join to view full profile
200 1st Street SWRochester, MN 55905
Dr. Xie is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2017 - 2020
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
Cleveland Clinic Lerner College of MedicineClass of 2014, MD
Princeton UniversityPhD, Organic Chemistry, 2004 - 2009- Fudan UniversityBS, Chemistry, 2000 - 2004
Certifications & Licensure
FL State Medical License 2020 - 2028
MN State Medical License 2017 - 2027
SD State Medical License Active through 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study.Fares Jamal, Cody Eslinger, Abdullah Alsulaiman, Tanios Bekaii-Saab, Hao Xie
Journal of Gastrointestinal Oncology. 2026-08-31 - Epigenomic profiling links IGF2 overexpression to anthracycline resistance in colorectal cancer organoids.Tara L Hogenson, William J Phillips, Merih D Toruner, Zachry S Poshusta, Luciana L Almada
JCI Insight. 2026-08-24 - Perineural spread of colorectal carcinoma into the sciatic nerve with positive circulating tumor DNA test: illustrative case.Pavlos Texakalidis, Cara C Prideaux, P James B Dyck, Hao Xie, Robert J Spinner
Journal of Neurosurgery. Case Lessons. 2026-03-23
Lectures
- Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.2019 ASCO Annual Meeting - 6/1/2019
- Methylated DNA markers (MDMs) in primary (pCRC) and metastatic colorectal cancers (mCRC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?September 30th, 2026- Researchers Identify Mutations Linked to Primary KRAS G12C Inhibitor ResistanceMarch 5th, 2025
- Key Genetic Changes May Drive Primary Resistance of Colorectal and Pancreatic Cancers to KRAS G12C InhibitorsMarch 3rd, 2025
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
